Phase I trials with HLA-A*02 or HLA-A*03 survivin+ glioma patients treated with SurVaxM in incomplete Freund’s adjuvant (Montanide ISA-51) and GM-CSF (Sargramostim) reported vaccine-specific immune responses in 6 out of 8 participants. The gene discussed is BIRC5; the disease is central nervous system cancer.